These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20173087)

  • 1. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
    Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
    J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S; Floot B; van der Vange N; Stewart FA
    Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
    Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
    Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
    Sugarbaker PH; Stuart OA; Carmignani CP
    Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
    Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
    Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
    de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
    Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
    Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
    van Ruth S; Mathôt RA; Sparidans RW; Beijnen JH; Verwaal VJ; Zoetmulder FA
    Clin Pharmacokinet; 2004; 43(2):131-43. PubMed ID: 14748621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
    Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
    BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
    Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
    Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
    Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
    Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
    Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
    Kusamura S; Younan R; Baratti D; Costanzo P; Favaro M; Gavazzi C; Deraco M
    Cancer; 2006 Mar; 106(5):1144-53. PubMed ID: 16456817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
    Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.
    Gilly FN; Beaujard A; Glehen O; Grandclement E; Caillot JL; Francois Y; Sadeghi-Looyeh B; Gueugniaud PY; Garbit F; Benoit M; Bienvenu J; Vignal J
    Anticancer Res; 1999; 19(3B):2317-21. PubMed ID: 10472351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.